Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.61 |
| ▸ | FNTB | P49356 | 19/20 | 0.61 |
| ▸ | PGGT1B | P53609 | 13/20 | 0.61 |
| ▸ | NRAS | P01111 | 1/20 | 0.54 |
| ▸ | HRAS | P01112 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657803 | 0.86 | FNTA (0.61) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7593695 | 0.85 | FNTA (0.59) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7591010 | 0.84 | FNTA (0.58) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7589214 | 0.82 | FNTA (0.56) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL7747644 | 0.79 | FNTA (0.37) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7662196 | 0.76 | FNTA (0.68) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL28275795 | 0.73 | FNTA (0.67) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL3498157 | 0.73 | FNTA (0.78) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7592794 | 0.72 | FNTA (0.67) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL3500206 | 0.72 | FNTA (0.84) | FNTAFNTBPGGT1BNRASHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6335343-B1 | IMIDAZOL-5-YLALKYLPIPERIZINE DERIVATIVES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. | 2002-01-01 | — | — | US | claimed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | claimed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| US-6335343-B1 | IMIDAZOL-5-YLALKYLPIPERIZINE DERIVATIVES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. | 2002-01-01 | — | — | US | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | FNTA 2/4885FNTB 7/4885PGGT1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.